RNS Number : 4748M


21 January 2021


("IXICO" or the "Company")

Results of AGM

IXICO plc (AIM: IXI), the AI digital technologies company serving neuroscience, announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:

 Resolution   Description            Total        % Votes   Total Votes   Withheld 
                                      Votes                  Against 
 1            Reports and Accounts   30,185,052   99.95%    15,600        400 
             ---------------------  -----------  --------  ------------  --------- 
 2            Re-election of 
              Re-election of 
               Mark Warne            30,185,152   99.95%    15,900        0 
              Re-election of 
               John Bradshaw         30,185,452   99.95%    15,600        0 
             ---------------------  -----------  --------  ------------  --------- 
 3             of Auditors           30,065,960   99.57%    128,100       6,992 
             ---------------------  -----------  --------  ------------  --------- 
              Allotment of 
 4             Securities            30,180,960   99.94%    17,100        2,992 
             ---------------------  -----------  --------  ------------  --------- 
              Disapply Pre-Emption 
 5             Provisions            30,180,010   99.94%    18,050        2,992 
             ---------------------  -----------  --------  ------------  --------- 
              Amendment of 
               rule 3.6.1 of 
               the Company's 
               2014 EMI Share 
 6             Option Plan           30,165,610   99.89%    33,350        1,992 
             ---------------------  -----------  --------  ------------  --------- 

For further information please contact:

 IXICO plc                                      +44 (0)20 3763 7498 
 Giulio Cerroni, Chief Executive Officer 
  Grant Nash, Chief Financial Officer 
 Cenkos Securities PLC (Nominated adviser 
  and sole broker)                              +44 (0)20 7397 8900 
 Giles Balleny / Max Gould (Corporate 
 Michael F Johnson / Russell Kerr 
 Walbrook PR Ltd                                +44 (0)20 7933 8780 
 Paul McManus / Lianne Cawthorne               IXICO@walbrookpr.com 
 Alice Woodings 


IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

   More information is available on   www.IXICO.com   and follow us on Twitter @IxicOplc 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

January 21, 2021 06:05 ET (11:05 GMT)